Caricamento...
Screening for potent and selective anticlostridial leads among FDA-approved drugs
Clostridium difficile is a leading cause of morbidity and mortality particularly in hospital settings. In addition, treatment is very challenging due to the scarcity of effective therapeutic options. Thus, there remains an unmet need to identify new therapeutic agents capable of treating C. difficil...
Salvato in:
| Pubblicato in: | J Antibiot (Tokyo) |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7211121/ https://ncbi.nlm.nih.gov/pubmed/32132676 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41429-020-0288-3 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|